Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 10, 2022 16:05 ET | Source: Akero Therapeutics

Akero Therapeutics to Present at Upcoming Healthcare Conferences in November

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
November 07, 2022 07:30 ET | Source: Akero Therapeutics

Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
November 04, 2022 07:00 ET | Source: Akero Therapeutics

Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
October 11, 2022 16:01 ET | Source: Akero Therapeutics

Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
September 19, 2022 16:01 ET | Source: Akero Therapeutics

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
September 14, 2022 20:07 ET | Source: Akero Therapeutics

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
September 14, 2022 07:18 ET | Source: Akero Therapeutics

In der HARMONY-Studie der Phase 2b von Akero Therapeutics wurde in der 50-mg- und der 28-mg-EFX-Dosisgruppe nach 24 Wochen statistische Signifikanz bei primären und sekundären histologischen Endpunkten erzielt

In den Gruppen mit 50 mg (41 %) und 28 mg (39 %) wurde im Vergleich zu Placebo (20 %) eine doppelt so hohe Anzahl von Patienten mit mindestens einstufiger Verbesserung der Fibrose ohne...
September 14, 2022 07:18 ET | Source: Akero Therapeutics

Dans l'étude HARMONY de phase 2b d'Akero Therapeutics, les doses de 50 mg et 28 mg d'EFX ont atteint la signification statistique sur les critères d'évaluation histologique primaires et secondaires après 24 semaines

Les groupes recevant 50 mg (41 %) et 28 mg (39 %) ont affiché une amélioration d'au moins 1 stade de la fibrose sans aggravation de la NASH, le double par rapport au placebo (20 %) Les groupes...
September 13, 2022 16:01 ET | Source: Akero Therapeutics

Akero Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
September 13, 2022 06:00 ET | Source: Akero Therapeutics

In Akero Therapeutics’ Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks

50mg (41%) and 28mg (39%) groups demonstrated ≥1 stage improvement in fibrosis without worsening of NASH, double the placebo rate (20%) 50mg (76%) and 28mg (47%) groups demonstrated NASH resolution...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right